In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Gavin Anderson, a man of many hats all orbiting around technology and business.
In the UK, one in 50 adults is living with a chronic wound,1 leading to more than £8 billion in healthcare costs in 2017/2018.2 However, these numbers are likely to be
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh